Cargando…
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial to identify which patients are suited for CD47-targeted therapy. In this respect, expression of the pro-phagocyti...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358615/ https://www.ncbi.nlm.nih.gov/pubmed/30710089 http://dx.doi.org/10.1038/s41467-018-08013-z |